Solid Dosage
With our comprehensive portfolio of oral solid dosage solutions, we can supply full process lines with containment interfaces for process steps from API and excipient dispensing, dry milling, powder collection and blending through to tableting and coating.
With an increasing emphasis on both operator safety and product protection, the commercial-scale production of oncology drugs, hormonal products and/or other highly potent compounds has been put under the pharmaceutical spotlight in recent years.
Eliminating the need for cumbersome isolation suits to prevent operators being exposed to hazardous substance and avoid cross-contamination with other products manufactured in the same facility, GEA’s approach is to use containment interfaces (the BUCK® MC high-containment range and disposable Hicoflex® products) to ensure compliance with global regulatory cGMP requirements.
Experts in contained material handling, closed product processing, gentle product treatment, the efficient recovery of active ingredients and reliable scale-up, we supply modules, components and fully integrated batch and continuous lines for the production of oncology drugs and other therapeutic agents that deliver increased yields and reduced cycle times.
From R&D-scale and standalone production equipment to contained production lines, we understand the absolute importance of preventing cross-contamination in the production area, protecting both people and products, and working within Real Daily Intake (RDI) and Acceptable Daily Intake (ADI) limits with up to occupational exposure band (OEB) 5 drugs.
GEA has a wealth of expertise and an unparalleled depth of experience in the field of containment. The company not only offers a comprehensive range of robust and compliant containment products, it also boasts unrivaled experience in identifying the most appropriate solution and a thorough understanding of containment risk analysis.
Showing 4 of 25
Combining process monitoring using online analyzers, together with solid process engineering principles and advanced process modelling techniques will enable processes to be actively controlled in order to compensate for input variations.
Innovative CIP concepts of GEA meet comprehensive high standards. Our experts guarantee product safety at every point of the process. Every upgrade is adapted to individual local conditions and customer requirements and leads to noticeable savings.
Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.
The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.
What if your favorite chocolate didn’t require cocoa beans and your coffee was locally produced? As climate disruption, price hikes and ethical concerns hit two of our most beloved indulgences, scientists are reimagining how we produce them – using microbes, not monocultures. The goal: preserve the flavor and properties of coffee and chocolate while minimizing carbon emissions and improving food resilience.
Ports now compete not just on logistics, but on sustainability. At Greece’s Piraeus port, an advanced processing and recovery facility recycles ship waste oil into fuel. Equipped with GEA’s high-performance centrifuges, it sets a new benchmark for state-of-the-art, environmentally responsible port operations.
The 2022 CO2 shortage forced breweries to review their dependency on global supply chains. Many were forced to close, unable to carbonate their products. At its breweries in Germany, OeTTINGER GETRÄNKE is turning its own CO2 into a powerful lever for independence and sustainability – with the help of CO2 recovery technology from GEA.